RxDoctor Payments Data

Michael Brodowski, MD

Internal Medicine · Syracuse, NYNPI 1902896012

Payments from drug & device makers

$817in general payments, 2019–2025

Across 13 payments — averaging $62.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$437
  • Neurocrine Biosciences, Inc.$132
  • Braeburn Inc.$88
  • Lilly USA, LLC$82
  • Teva Pharmaceuticals USA, Inc.$37
  • Johnson & Johnson$24
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$817100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$817 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$100,899
Medicare patients
459
Services billed
935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$41,961
TrulicityDulaglutide29$27,199
RexultiBrexpiprazole18$24,174
XareltoRivaroxaban40$21,091
NuedextaDextromethorphan Hbr/Quinidine23$17,307
VeltassaPatiromer Calcium Sorbitex32$11,711
RetacritEpoetin Alfa-Epbx17$9,478
JardianceEmpagliflozin15$8,725
LinzessLinaclotide13$7,434
Mirtazapine94$3,269
Levothyroxine Sodium239$3,215
MyrbetriqMirabegron12$2,782
Esomeprazole Magnesium19$2,246
Rivastigmine26$2,133
Metoprolol Succinate75$1,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$82$27,19929 claims
Johnson & JohnsonXarelto$24$21,09140 claims
Avanir Pharmaceuticals, Inc.Nuedexta$437$17,30723 claims
AbbVieLinzess$17$7,43413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →